Market News AIOpen the app

GENB stock news · Generate Biomedicines

Stories about Generate Biomedicines (GENB) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for GENB

Follow Generate Biomedicines (GENB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GENB
Free on the App Store and Google Play, or on the web.
  1. Nov 22, 2026, 9:07 AM ET · Opinion

    Morgan Stanley lowered its price target for Generate Biomedicines from $22 to $21.

    Neutral

    Morgan Stanley cut its GENB target from $22 to $21 but kept its favorable rating. The mixed update does not clearly change the company's outlook.

  2. Oct 14, 2026, 11:37 AM ET · Deal

    Generate Biomedicines teams up with Zealand Pharma to create AI drugs for the growing obesity market.

    Good for GENB

    Generate Biomedicines has a new drug-development partnership that brings upfront cash and possible future payments. The later payments depend on progress, so the deal is a positive step, not a sure payoff.